3[1]Friend Laender MA, Hricik DE. Optimal end-stage renal disease therapy for the patients with diabetes mellitus. Semin Nephrol 1997; 17(4) :331-345.
4[4]Kumar Sharma, Tracy A. Mcgowan. TGF-β1 in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Reviews 2000; 11:115-123.
5[5]Studer RK, Craven PA, Deruberts FR, et al. Low density lipoproteins stimulation of mesangial cell fibronectin synthesis:role of protein kinase C and TGF-β1. J Lab Clin Med 1995;125: 86-90.
6[6]Sharma K, Guo J, Jin Y. Neutralization of TGF-beta by antiTGF-beta antibody attenuates kidney hypertrophy and enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996 ;45(4) :552-530.
8Bedford C, Peacey SR, Robinson R, et al. Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycemia? Diabetes Care2000;23(7):1022-1023.
9Balkan B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall study, the Paris prospective study, and the Helsinki policemen study. Diabetees Care
10Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulirn secretion, and insulin sensitivity in non-obese and obese Japanese subjects. Diabetes Care1997;20:1562.
